Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 0.79
(-5.94%)
SEK 0.79
(-5.94%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 43.89 Million SEK | 6.23% |
| 2022 | 41.32 Million SEK | 88.59% |
| 2021 | 21.91 Million SEK | 202.88% |
| 2020 | 7.23 Million SEK | 29.8% |
| 2019 | 5.57 Million SEK | -15.08% |
| 2018 | 6.56 Million SEK | 32.72% |
| 2017 | 4.94 Million SEK | 34.48% |
| 2016 | 3.67 Million SEK | 138.46% |
| 2015 | 1.54 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | 22.06 Million SEK | 100.0% |
| 2023 Q3 | 10.91 Million SEK | -50.54% |
| 2023 Q4 | 10.91 Million SEK | 0.0% |
| 2023 FY | 43.89 Million SEK | 6.23% |
| 2023 Q1 | 11.03 Million SEK | -52.39% |
| 2022 Q4 | 23.17 Million SEK | 100.0% |
| 2022 Q2 | 18.14 Million SEK | 100.0% |
| 2022 Q1 | 9.07 Million SEK | -33.4% |
| 2022 FY | 41.32 Million SEK | 88.59% |
| 2022 Q3 | 11.58 Million SEK | -36.14% |
| 2021 Q2 | 8.28 Million SEK | -58.85% |
| 2021 FY | 21.91 Million SEK | 202.88% |
| 2021 Q1 | 20.13 Million SEK | 1037.5% |
| 2021 Q4 | 13.62 Million SEK | 69.43% |
| 2021 Q3 | 8.03 Million SEK | -2.99% |
| 2020 Q3 | 1.77 Million SEK | 6.46% |
| 2020 Q2 | 1.66 Million SEK | -18.12% |
| 2020 Q1 | 2.03 Million SEK | 13.78% |
| 2020 FY | 7.23 Million SEK | 29.8% |
| 2020 Q4 | 1.77 Million SEK | 0.0% |
| 2019 Q2 | 1.55 Million SEK | 158.64% |
| 2019 Q1 | 602 Thousand SEK | -74.43% |
| 2019 FY | 5.57 Million SEK | -15.08% |
| 2019 Q4 | 1.78 Million SEK | 9.58% |
| 2019 Q3 | 1.62 Million SEK | 4.62% |
| 2018 Q2 | 1.4 Million SEK | -34.31% |
| 2018 FY | 6.56 Million SEK | 32.72% |
| 2018 Q4 | 2.35 Million SEK | 257.21% |
| 2018 Q3 | 659 Thousand SEK | -53.16% |
| 2018 Q1 | 2.14 Million SEK | 93.5% |
| 2017 Q3 | 980 Thousand SEK | -47.26% |
| 2017 Q1 | 1.85 Million SEK | 213.32% |
| 2017 FY | 4.94 Million SEK | 34.48% |
| 2017 Q4 | 1.1 Million SEK | 12.96% |
| 2017 Q2 | 1.85 Million SEK | 0.0% |
| 2016 Q4 | 593 Thousand SEK | 0.0% |
| 2016 FY | 3.67 Million SEK | 138.46% |
| 2015 FY | 1.54 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 24.457% |
| Ziccum AB (publ) | 3.74 Million SEK | -1071.497% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 92.874% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 13.051% |
| Mendus AB (publ) | 28.48 Million SEK | -54.091% |
| Genovis AB (publ.) | 158.23 Million SEK | 72.258% |
| Intervacc AB (publ) | 8.01 Million SEK | -447.673% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -903.567% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 74.245% |
| Aptahem AB (publ) | 2.63 Million SEK | -1568.638% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -4141.159% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -56907.792% |
| Fluicell AB (publ) | 3.33 Million SEK | -1215.039% |
| Saniona AB (publ) | 16.84 Million SEK | -160.665% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -167.544% |
| Biovica International AB (publ) | 7.29 Million SEK | -502.14% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -3548.878% |
| AcouSort AB (publ) | 10.55 Million SEK | -316.036% |
| Xintela AB (publ) | 78 Thousand SEK | -56176.923% |
| Abliva AB (publ) | 137 Thousand SEK | -31940.876% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 23.792% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -2079.543% |
| OncoZenge AB (publ) | 3000.00 SEK | -1463100.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -28220.0% |
| CombiGene AB (publ) | 5.54 Million SEK | -691.758% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 96.363% |
| Camurus AB (publ) | 1.71 Billion SEK | 97.443% |
| Corline Biomedical AB | 25.03 Million SEK | -75.374% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -673.089% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -5988.211% |
| I-Tech AB | 120.86 Million SEK | 63.681% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 67.265% |
| Cyxone AB (publ) | 5.14 Million SEK | -752.681% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -522.638% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -311.601% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -290.879% |
| Nanologica AB (publ) | 1.44 Million SEK | -2941.996% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -82722.642% |
| BioInvent International AB (publ) | 71.46 Million SEK | 38.573% |
| Alzinova AB (publ) | 270 Thousand SEK | -16157.778% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -24.634% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -2900.369% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -1455.493% |
| Simris Alg AB (publ) | 4.35 Million SEK | -908.176% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -33666.154% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 81.613% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -190752.174% |